<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02718365</url>
  </required_header>
  <id_info>
    <org_study_id>TSCI002</org_study_id>
    <nct_id>NCT02718365</nct_id>
  </id_info>
  <brief_title>Comparison Between Wedge Resection and Segmentectomy for Ground Glass Opacity- Dominant Stage IA NSCLC</brief_title>
  <official_title>A Multi-center, Prospective, Randomized Controlled Clinical Trial: Comparison Between Wedge Resection and Segmentectomy in the Surgical Treatment of Ground Glass Opacity-dominant Stage IA Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>West China Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>West China Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate whether the long-term outcome and safety of wedge&#xD;
      resection are comparable to segmentectomy for the surgical treatment of early stage (IA)&#xD;
      non-small cell lung cancer (NSCLC). Zhang et al. performed a meta-analysis of 53 studies and&#xD;
      suggested that sublobectomy achieved a survival rate comparable to lobectomy in a selected&#xD;
      population of patients with Stage I NSCLC. However, one critical question needs to be&#xD;
      addressed, that is, does sublobectomy require segmentectomy or wedge resection? Cho et al.&#xD;
      reported that, for pulmonary ground glass opacity (GGO) nodules (Stage IA NSCLC), wedge&#xD;
      resection achieved a 5-year survival rate of 98.6% in the pure GGO group and 95.5% in the&#xD;
      mixed GGO group. Cho et al. cautioned against performing wedge resection for mixed GGO&#xD;
      nodules with GGO component ≤ 75%, due to the high recurrence rate. When radiology shows that&#xD;
      the GGO component is ≥75%, pathology usually finds that the lesions are non-invasive.&#xD;
      Therefore, these lesions are potential candidates for wedge resection. This randomized&#xD;
      clinical trial is to assess whether wedge resection can be established as a standard&#xD;
      treatment for Stage IA NSCLC with tumor size ≤ 2 cm and GGO component ≥ 75%.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Selection procedures: When a case meets the inclusion criteria and does not meet&#xD;
           exclusion criteria, the research assistant of each research participating center will&#xD;
           fill out the Eligibility Application Form and submit it to the Research Committee for&#xD;
           reviewing whether the case is eligible for the trial. The following rules will be&#xD;
           strictly applied:&#xD;
&#xD;
             1. The application and confirmation of eligibility should be preoperatively completed&#xD;
                and any postoperative application will not be accepted.&#xD;
&#xD;
             2. If the Eligibility Application Form is incomplete, it must be returned to be&#xD;
                completed; otherwise, it will not be accepted.&#xD;
&#xD;
             3. After being approved by the Research Committee, the case will be assigned a number&#xD;
                (Baseline Number, BN) and an Eligibility Confirmation Notice will be sent to the&#xD;
                applicant.&#xD;
&#xD;
             4. After each research participating center receives the Eligibility Confirmation&#xD;
                Notice, the research assistant of each center is responsible for the custody and&#xD;
                documentation.&#xD;
&#xD;
             5. Once being selected for registration, the content of the Eligibility Application&#xD;
                Form will be input into the database and the case's eligibility is not allowed to&#xD;
                be cancelled, that is, the relevant information cannot be deleted from the&#xD;
                database, unless the patient declines the information to be used in this study.&#xD;
&#xD;
             6. The data center will not accept any duplicated applications for any single case. If&#xD;
                this happens, the first registered data will be used (i.e., the first time BN).&#xD;
&#xD;
             7. In cases of duplicated applications or registration errors, the research assistant&#xD;
                of each research participating center shall contact the Research Committee as soon&#xD;
                as possible for liaison and documentation.&#xD;
&#xD;
        2. Qualification of the responsible surgeons who participate in this study: the responsible&#xD;
           surgeons who participate in this study shall meet the following qualifications: 1) at&#xD;
           least have completed 20 cases of VATS segmentectomy; and 2) have passed the blind review&#xD;
           of his/her video records of the surgery.&#xD;
&#xD;
        3. Criteria for confirming operation quality: for the case to be included in the analysis,&#xD;
           the responsible surgeon shall submit the video or photo recordings of the surgery to the&#xD;
           Research Committee for evaluation of the surgical procedures.&#xD;
&#xD;
        4. Rules for handling the excluded patients identified intraoperatively: if the responsible&#xD;
           surgeon finds that the patient in operation meets the exclusion criteria, the case will&#xD;
           be excluded and the surgeon will follow the routine clinical practice of the research&#xD;
           participating center to decide subsequent treatments that are not specified in this&#xD;
           study protocol.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 7, 2017</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>5-year Progression-Free-Survival</measure>
    <time_frame>From date of the recruitment, assessed up to 60 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>3-year Progression-Free-Survival</measure>
    <time_frame>From date of the recruitment, assessed up to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5-year overall survival</measure>
    <time_frame>From date of the recruitment, assessed up to 60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary function in the first year after surgery</measure>
    <time_frame>From date of the 1 month\ 3 months\ 6 months\ 12 months after surgery in every recruited patient</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30-day Morbidity and mortality rates</measure>
    <time_frame>From date of the recruitment, assessed up to 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>10-year overall survival</measure>
    <time_frame>From date of the recruitment, assessed up to 120 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1382</enrollment>
  <condition>Lung Neoplasms</condition>
  <condition>Surgery</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Wedge resection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Segmentectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Wedge resection</intervention_name>
    <description>A wedge resection is the surgical removal of the lung tumor with a small portion of the lung that surrounds the tumor. Hilar and mediastinal lymph nodes should be resected or sampled.</description>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Segmentectomy</intervention_name>
    <description>A segmentectomy removes a segment of a lung lobe anatomically, or inclusion of a portion of adjacent segment, but does not remove the whole lung lobe. Hilar and mediastinal lymph nodes should be resected or sampled.</description>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          1. Preoperative thin-section computed tomography (TSCT) will fulfill all of the following&#xD;
             conditions:&#xD;
&#xD;
               -  Lung cancer is suspected.&#xD;
&#xD;
               -  Lesion size is more than 5 mm but equal to or less than 20 mm.&#xD;
&#xD;
               -  Consolidation/tumor (C/T) ratio is equal to or less than 0.25.&#xD;
&#xD;
               -  The center of the tumor is located in the outer third of the lung field.&#xD;
&#xD;
               -  Preoperative TSCT estimates a surgical margin of more than1.5 cm or the tumor's&#xD;
                  diameter.&#xD;
&#xD;
          2. Preoperative clinical staging: T1a-T1bN0M0 (according to UICC2017-8thTNM staging).&#xD;
&#xD;
          3. R0 resectable in segmentectomy and wedge resections plus mediastinal lymph node&#xD;
             resection.&#xD;
&#xD;
          4. Aged 18 to 75 years old.&#xD;
&#xD;
          5. No prior chemotherapy or thoracic radiation therapy for any malignant diseases.&#xD;
&#xD;
          6. Preoperative FEV1.0&gt;=1.0 L.&#xD;
&#xD;
          7. Performance status of ECOG 0 or 1.&#xD;
&#xD;
          8. Preoperative ASA scoring (American society of anesthesiology) class I -III.&#xD;
&#xD;
          9. Sufficient organ functions.&#xD;
&#xD;
         10. The patient agrees to participate in the trial and signs the informed consent form.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Quit smoking &lt;2 weeks.&#xD;
&#xD;
          2. Preoperative FEV1 &lt; 50% of the expected value.&#xD;
&#xD;
          3. Mediastinal lymph node metastasis confirmed by biopsy.&#xD;
&#xD;
          4. Pregnant or lactating women.&#xD;
&#xD;
          5. Serious mental illness.&#xD;
&#xD;
          6. With other malignant disease history within 5 years.&#xD;
&#xD;
          7. With the history of unstable angina or myocardial infarction within 6 months.&#xD;
&#xD;
          8. With the history of cerebral infarction or cerebral hemorrhage within 6 months.&#xD;
&#xD;
          9. With the history of sustained systemic corticosteroid therapy within 1 month.&#xD;
&#xD;
         10. The patient requires simultaneous surgical treatment of other diseases.&#xD;
&#xD;
         11. TSCT shows that the lesion is located in the right middle lobe.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lunxu Liu, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Thoracic Surgery, West China Hospital, Sichuan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hu Liao, M.D.</last_name>
    <phone>+86 28 85422494</phone>
    <email>liaotiger_198653@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Liyan Chen, M.Sc.</last_name>
    <phone>+86 28 85422494</phone>
    <email>lilianchan7786@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>West China Hospital, Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hu Liao, MD</last_name>
    </contact>
    <investigator>
      <last_name>Lunxu Liu, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hu Liao, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>National Lung Screening Trial Research Team, Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, Gareen IF, Gatsonis C, Marcus PM, Sicks JD. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011 Aug 4;365(5):395-409. doi: 10.1056/NEJMoa1102873. Epub 2011 Jun 29.</citation>
    <PMID>21714641</PMID>
  </reference>
  <reference>
    <citation>Zhang Y, Sun Y, Wang R, Ye T, Zhang Y, Chen H. Meta-analysis of lobectomy, segmentectomy, and wedge resection for stage I non-small cell lung cancer. J Surg Oncol. 2015 Mar;111(3):334-40. doi: 10.1002/jso.23800. Epub 2014 Oct 16.</citation>
    <PMID>25322915</PMID>
  </reference>
  <reference>
    <citation>Hida Y, Teramura K, Muto J, Ohtaka K, Hase R, Nakada R, Watanabe Y, Matsui Y, Kaga K. [Indication of limited pulmonary resection for small-sized lung cancer based on preoperative clinical data]. Kyobu Geka. 2012 Jan;65(1):52-7. Japanese.</citation>
    <PMID>22314158</PMID>
  </reference>
  <reference>
    <citation>Tsutani Y, Miyata Y, Nakayama H, Okumura S, Adachi S, Yoshimura M, Okada M. Appropriate sublobar resection choice for ground glass opacity-dominant clinical stage IA lung adenocarcinoma: wedge resection or segmentectomy. Chest. 2014 Jan;145(1):66-71. doi: 10.1378/chest.13-1094.</citation>
    <PMID>24551879</PMID>
  </reference>
  <reference>
    <citation>Cho JH, Choi YS, Kim J, Kim HK, Zo JI, Shim YM. Long-term outcomes of wedge resection for pulmonary ground-glass opacity nodules. Ann Thorac Surg. 2015 Jan;99(1):218-22. doi: 10.1016/j.athoracsur.2014.07.068. Epub 2014 Nov 15.</citation>
    <PMID>25440277</PMID>
  </reference>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 4, 2015</study_first_submitted>
  <study_first_submitted_qc>March 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2016</study_first_posted>
  <last_update_submitted>October 9, 2020</last_update_submitted>
  <last_update_submitted_qc>October 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>West China Hospital</investigator_affiliation>
    <investigator_full_name>Lunxu Liu</investigator_full_name>
    <investigator_title>Professor and Chair of Department of Thoracic Surgery</investigator_title>
  </responsible_party>
  <keyword>Lung Neoplasms</keyword>
  <keyword>Surgery</keyword>
  <keyword>VATS</keyword>
  <keyword>GGO</keyword>
  <keyword>GGN</keyword>
  <keyword>Segmentectomy</keyword>
  <keyword>Wedge Resection</keyword>
  <keyword>Prognosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

